Quick Facts
| Property | Value |
|---|---|
| Category | Regenerative / Tissue Repair Peptide |
| Risk Level | Low/Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | Twice Daily |
| Estimated Half-Life | Approximately 2–4 Hours |
| Primary Research Interest | Tissue Repair / Recovery / Inflammation Support |
This material is provided strictly for educational and informational purposes related to peptide research and regenerative compounds. BPC-157 is a biologically active experimental peptide with limited large-scale human safety data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 250 mcg = 0.075 mL (7.5 units)
• 1000 mcg = 0.300 mL (30.0 units)
2. Route of Administration
BPC-157 is most commonly administered as a subcutaneous injectable peptide compound.
- Primary Route: SubQ Injection
- Alternative Routes Discussed: Oral and intramuscular discussions exist in anecdotal communities
- Administration Notes: Some users prefer localized injections near injured tissues, though systemic effects are also commonly reported
3. Typical Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 250–1000 mcg daily
- Frequency: BID (twice daily)
- Cycle Length: 4–12 weeks on, PRN (as needed)
- Special Notes: One of the biggest ongoing discussions is whether injecting “near the injury” matters. Community opinions vary. Some users strongly believe localized injections improve outcomes, while others report systemic benefits regardless of injection site. There is currently no strong human evidence proving true site-specific targeting.
4. Summary
BPC-157 (Body Protection Compound-157) is an experimental peptide originally derived from gastric protective protein research and widely discussed for its potential regenerative and tissue repair properties.
Research and anecdotal interest in BPC-157 primarily center around tendon repair, soft tissue recovery, inflammation modulation, gastrointestinal protection, and accelerated healing support.
5. Mechanism of Action
BPC-157 is believed to influence multiple regenerative signaling pathways associated with angiogenesis, collagen synthesis, inflammation modulation, and tissue remodeling.
Potential downstream effects discussed in research include:
- Enhanced blood vessel formation
- Improved collagen organization
- Reduced inflammatory signaling
- Accelerated tendon and ligament recovery
- Potential gastrointestinal protective effects
The peptide is frequently discussed as a broad-spectrum regenerative compound rather than a highly targeted signaling agent.
6. Potential Benefits
- Potential tendon and ligament recovery support
- Reduced inflammation signaling
- Accelerated soft tissue healing
- Possible gastrointestinal protective effects
- Improved recovery from training stress or injury
- Potential angiogenesis support
7. Potential Risks / Side Effects
Low/Moderate
- Injection site irritation
- Fatigue
- Nausea
- Headaches
- Dizziness
- Potential abnormal angiogenesis concerns
- Limited long-term human safety data
8. Half-Life
BPC-157 is commonly discussed as having an estimated half-life in the range of approximately 2–4 hours.
Because of this relatively short duration, divided daily administration protocols are frequently discussed.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Use alongside experimental angiogenic compounds
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Experimental regenerative medicine literature
- Peer-reviewed tissue repair journals
CKF Tide Tables 